Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.45 USD
Change Today +0.20 / 1.16%
Volume 794.0K
HALO On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:20 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALO) Snapshot

Open
$17.20
Previous Close
$17.25
Day High
$17.58
Day Low
$16.97
52 Week High
05/19/15 - $17.63
52 Week Low
05/22/14 - $7.26
Market Cap
2.2B
Average Volume 10 Days
1.2M
EPS TTM
$-0.45
Shares Outstanding
127.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HALOZYME THERAPEUTICS INC (HALO)

halozyme therapeutics inc (HALO) Related Businessweek News

No Related Businessweek News Found

halozyme therapeutics inc (HALO) Details

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. The company is also developing PEGPH20, a new molecular entity that is in Phase II clinical trials for the treatment of metastatic pancreatic cancer, as well as in Phase I clinical trial for the treatment of non-small cell lung cancer; and Hylenex recombinant for use as pre-treatment in patients with type 1 diabetes using pumps and recombinant human cathepsin L (HTI-501) for the treatment of cellulite. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd., Hoffmann-La Roche, Inc., Baxter Healthcare Corporation, Pfizer Inc., and Janssen Biotech, Inc. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

153 Employees
Last Reported Date: 03/2/15
Founded in 1998

halozyme therapeutics inc (HALO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.6M
Chief Financial Officer and Vice President
Total Annual Compensation: $364.9K
Compensation as of Fiscal Year 2014.

halozyme therapeutics inc (HALO) Key Developments

Halozyme Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year of 2015

Halozyme Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. Revenues for the first quarter of 2015 were $18.7 million, compared to $12.0 million for the first quarter of 2014. Revenues in the first quarter included $6.8 million in royalty revenue from sales of products under collaboration agreements, $6.1 million in product sales of bulk rHuPH20 for use in manufacturing collaboration products for Roche, $3.8 million in Hylenex recombinant (hyaluronidase human injection) product sales, and $2.0 million in collaboration revenues. The net loss for the first quarter of 2015 was $15.1 million, or $0.12 per basic and diluted share, compared to a net loss for the first quarter of 2014 of $26.5 million, or $0.22 per basic and diluted share. Operating loss was $13,911,000 compared to $25,219,000 a year ago. The company provided earnings guidance for the full year of 2015. For the full year 2015, the company reiterated its previously disclosed guidance of net revenues to be in the range of $85 million to $95 million. Net cash burn to be between $35 million to $45 million.

Halozyme Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:40 AM

Halozyme Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:40 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: David A. Ramsay, Chief Financial Officer and Vice President.

Halozyme Therapeutics, Inc. to Report Q1, 2015 Results on May 11, 2015

Halozyme Therapeutics, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $17.45 USD +0.20

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $14.80 USD +0.13
Valeant Pharmaceuticals International Inc C$291.64 CAD +6.41
View Industry Companies
 

Industry Analysis

HALO

Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.7x
Price/Book 56.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit www.halozyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.